Financial reports
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
23 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
Current reports
8-K
Candel Therapeutics Announces Upcoming Presentations
25 Apr 24
8-K
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
11 Apr 24
8-K
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
9 Apr 24
8-K
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
4 Apr 24
8-K
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28 Mar 24
8-K
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
6 Mar 24
8-K
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
13 Feb 24
8-K
Departure of Directors or Certain Officers
12 Jan 24
8-K
Other Events
3 Jan 24
8-K
Departure of Directors or Certain Officers
14 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
28 Mar 24
424B5
Prospectus supplement for primary offering
13 Feb 24
S-8
Registration of securities for employees
30 Mar 23
S-3
Shelf registration
5 Aug 22
S-8
Registration of securities for employees
29 Mar 22
S-8
Registration of securities for employees
29 Jul 21
424B4
Prospectus supplement with pricing info
28 Jul 21
S-1/A
IPO registration (amended)
26 Jul 21
S-1/A
IPO registration (amended)
21 Jul 21
8-A12B
Registration of securities on exchange
19 Jul 21
Other
EFFECT
Notice of effectiveness
15 Aug 22
CORRESP
Correspondence with SEC
10 Aug 22
UPLOAD
Letter from SEC
9 Aug 22
EFFECT
Notice of effectiveness
27 Jul 21
CORRESP
Correspondence with SEC
26 Jul 21
CORRESP
Correspondence with SEC
26 Jul 21
CERT
Certification of approval for exchange listing
22 Jul 21
CORRESP
Correspondence with SEC
20 Jul 21
CORRESP
Correspondence with SEC
20 Jul 21
CORRESP
Correspondence with SEC
20 Jul 21
Ownership